International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 195-204
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months
Güray SAYDAM1, Ibrahim C. HAZNEDAROGLU2, Yesim TEMIZ3, Teoman SOYSAL4, Gulsan SUCAK5, Murat TOMBULOGLU1, Hakan OZDOGU6, Selim YAVUZ7, Abdullah ALTINTAS8, Gulsum OZET9, Zafer GULBAS10, Burhan FERHANOGLU4, Osman ILHAN11
1Ege University Faculty of Medicine Department of Hematology, İzmir, TURKEY
2Hacettepe University Faculty of Medicine Department of Hematology, Ankara, TURKEY
3BMS Pharmaceutical Company, Medical Department, Istanbul, TURKEY
4Istanbul University Cerrahpasa Faculty of Medicine Department of Hematology, Istanbul, TURKEY
5Gazi University Faculty of Medicine Department of Hematology, Ankara, TURKEY
6Baskent University Faculty of Medicine Department of Hematology, Adana, TURKEY
7Istanbul University Faculty of Medicine Department of Hematology, Istanbul, TURKEY
8Dicle University Faculty of Medicine Department of Hematology, Diyarbakır, TURKEY
9Ankara Numune Hospital Division of Hematology, Ankara, TURKEY
10Osmangazi University Faculty of Medicine Department of Hematology, Tokat, TURKEY
11Ankara University Faculty of Medicine Department of Hematology, Ankara, TURKEY
Keywords: Dasatinib, Compassionate use program, Philadelphia positive leukemias, CML
This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94±4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72±171.29, 714.29±106.90, and 569.23±160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.
Güray SAYDAM1, Ibrahim C. HAZNEDAROGLU2, Yesim TEMIZ3, Teoman SOYSAL4, Gulsan SUCAK5, Murat TOMBULOGLU1, Hakan OZDOGU6, Selim YAVUZ7, Abdullah ALTINTAS8, Gulsum OZET9, Zafer GULBAS10, Burhan FERHANOGLU4, Osman ILHAN11
1Ege University Faculty of Medicine Department of Hematology, İzmir, TURKEY
2Hacettepe University Faculty of Medicine Department of Hematology, Ankara, TURKEY
3BMS Pharmaceutical Company, Medical Department, Istanbul, TURKEY
4Istanbul University Cerrahpasa Faculty of Medicine Department of Hematology, Istanbul, TURKEY
5Gazi University Faculty of Medicine Department of Hematology, Ankara, TURKEY
6Baskent University Faculty of Medicine Department of Hematology, Adana, TURKEY
7Istanbul University Faculty of Medicine Department of Hematology, Istanbul, TURKEY
8Dicle University Faculty of Medicine Department of Hematology, Diyarbakır, TURKEY
9Ankara Numune Hospital Division of Hematology, Ankara, TURKEY
10Osmangazi University Faculty of Medicine Department of Hematology, Tokat, TURKEY
11Ankara University Faculty of Medicine Department of Hematology, Ankara, TURKEY
Keywords: Dasatinib, Compassionate use program, Philadelphia positive leukemias, CML
This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94±4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72±171.29, 714.29±106.90, and 569.23±160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |